RapidAI Scores FDA Clearance, Bringing AI-Powered Stroke Assessment to the Interventional Suite

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson’s progression

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients

April 19, 2024

More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

November 20, 2024

Lantern Pharma and Oregon partner to develop cancer treatment

The alliance will identify biomarker signatures that can aid in stratifying tumours that are most responsive to the drug. Credit: YURIMA / Shutterstock.com. Lantern Pharma

May 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.